Jill Roberts Center for Inflammatory Bowel Disease

Publications

Found 29 results

Filters: Author is Scherl, Ellen J [Clear All Filters]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

V

Gordon BL, Galati J, Yang S, Katz PO, Scherl EJ. 2020. Vitamin C Deficiency: An Under-Recognized Condition in Crohn's Disease.. ACG Case Rep J. 7(7):e00424.

U

Panaccione R, Danese S, Sandborn WJ, O'Brien CD, Zhou Y, Zhang H, Adedokun OJ, Tikhonov I, Targan S, Abreu MT et al.. 2020. Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.. Aliment Pharmacol Ther. 52(11-12):1658-1675.

Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD. 2015. Ulcerative Colitis Care Pathway.. Gastroenterology. 149(1):238-45.

S

Zhang S, Dogan B, Guo C, Herlekar D, Stewart K, Scherl EJ, Simpson KW. 2020. Short Chain Fatty Acids Modulate the Growth and Virulence of Pathosymbiont and Host Response.. Antibiotics (Basel). 9(8)

Montrose DC, Scherl EJ, Bosworth BP, Zhou XKathy, Jung B, Dannenberg AJ, Hla T. 2013. S1P₁ localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity.. J Lipid Res. 54(3):843-51.

R

Kothary V, Scherl EJ, Bosworth B, Jiang Z-D, Dupont HL, Harel J, Simpson KW, Dogan B. 2013. Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps.. Antimicrob Agents Chemother. 57(2):811-7.

Dogan B, Fu J, Zhang S, Scherl EJ, Simpson KW. 2018. Rifaximin decreases virulence of Crohn's disease-associated Escherichia coli and epithelial inflammatory responses.. J Antibiot (Tokyo). 71(5):485-494.

Scherl EJ, Kumar S, Warren RU. 2010. Review of the safety and efficacy of ustekinumab.. Therap Adv Gastroenterol. 3(5):321-8.

P

Poppers DM, Scherl EJ. 2008. Prophylaxis against Pneumocystis pneumonia in patients with inflammatory bowel disease: toward a standard of care.. Inflamm Bowel Dis. 14(1):106-13.

M

Castellanos JG, Woo V, Viladomiu M, Putzel G, Lima S, Diehl GE, Marderstein AR, Gandara J, Perez AR, Withers DR et al.. 2018. Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis.. Immunity. 49(6):1077-1089.e5.

Harris A, Eswaran S, Bosworth B, Gambarin-Gelwan M, Scherl EJ. 2007. Mesalamine-induced Pneumonitis and Serum Sickness-like Reaction.. Gastroenterol Hepatol (N Y). 3(11):875-7.

I

Scherl EJ. 2002. Irritable-inflammatory bowel disease: recognizing a new overlap syndrome and an enigma wrapped inside a puzzle.. Inflamm Bowel Dis. 8(5):373-4.

Dogan B, Suzuki H, Herlekar D, R Sartor B, Campbell BJ, Roberts CL, Stewart K, Scherl EJ, Araz Y, Bitar PP et al.. 2014. Inflammation-associated adherent-invasive Escherichia coli are enriched in pathways for use of propanediol and iron and M-cell translocation.. Inflamm Bowel Dis. 20(11):1919-32.

Craven M, Egan CE, Dowd SE, McDonough SP, Dogan B, Denkers EY, Bowman D, Scherl EJ, Simpson KW. 2012. Inflammation drives dysbiosis and bacterial invasion in murine models of ileal Crohn's disease.. PLoS One. 7(7):e41594.

Battat R, Lukin D, Scherl EJ, Pola S, Kumar A, Okada L, Yang L, Jain A, Siegel CA. 2021. Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease.. Inflamm Bowel Dis. 27(9):1443-1451.

Viladomiu M, Kivolowitz C, Abdulhamid A, Dogan B, Victorio D, Castellanos JG, Woo V, Teng F, Tran NL, Sczesnak A et al.. 2017. IgA-coated enriched in Crohn's disease spondyloarthritis promote T17-dependent inflammation.. Sci Transl Med. 9(376)

Zhang N, Yantiss RK, Nam H-S, Chin Y, Zhou XKathy, Scherl EJ, Bosworth BP, Subbaramaiah K, Dannenberg AJ, Benezra R. 2014. ID1 is a functional marker for intestinal stem and progenitor cells required for normal response to injury.. Stem Cell Reports. 3(5):716-24.

E

DeFilippis EM, Tabani S, Warren RU, Christos PJ, Scherl EJ. 2016. Exercise and Self-Reported Limitations in Patients with Inflammatory Bowel Disease.. Dig Dis Sci. 61(1):215-20.

Dogan B, Belcher-Timme HFacey, Dogan EI, Jiang Z-D, Dupont HL, Snyder N, Yang S, Chandler B, Scherl EJ, Simpson KW. 2018. Evaluation of Escherichia coli pathotypes associated with irritable bowel syndrome.. FEMS Microbiol Lett. 365(22)

Gerbarg PL, Jacob VE, Stevens L, Bosworth BP, Chabouni F, DeFilippis EM, Warren R, Trivellas M, Patel PV, Webb CD et al.. 2015. The Effect of Breathing, Movement, and Meditation on Psychological and Physical Symptoms and Inflammatory Biomarkers in Inflammatory Bowel Disease: A Randomized Controlled Trial.. Inflamm Bowel Dis. 21(12):2886-96.

C

Longman RS, Diehl GE, Victorio DA, Huh JR, Galan C, Miraldi ER, Swaminath A, Bonneau R, Scherl EJ, Littman DR. 2014. CX₃CR1⁺ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22.. J Exp Med. 211(8):1571-83.

Weinstock LB, Bosworth BP, Scherl EJ, Li E, Iroku U, Munsell MA, Mullen GE, Walters AS. 2010. Crohn's disease is associated with restless legs syndrome.. Inflamm Bowel Dis. 16(2):275-9.

DeFilippis EM, Longman R, Harbus M, Dannenberg K, Scherl EJ. 2016. Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies.. Curr Gastroenterol Rep. 18(3):13.

Huang C, Haritunians T, Okou DT, Cutler DJ, Zwick ME, Taylor KD, Datta LW, Maranville JC, Liu Z, Ellis S et al.. 2015. Characterization of genetic loci that affect susceptibility to inflammatory bowel diseases in African Americans.. Gastroenterology. 149(6):1575-86.

DeFilippis EM, Barfield E, Leifer D, Steinlauf A, Bosworth BP, Scherl EJ, Sockolow R. 2015. Cerebral venous thrombosis in inflammatory bowel disease.. J Dig Dis. 16(2):104-8.